- Redwood City, CA-based Guardant Health (NASDAQ:GH) has filed a prospectus for a $100M IPO.
- The oncology firm provides liquid biopsy molecular diagnostic testing services for cancer. Lead test is Guardant360, a 73-gene panel for advanced-stage cancer.
- 2018 Financials (6 mo.)($M): Revenue: 36.1 (+93.0%); Net Loss: (35.5) (+10.4%); Cash Consumption: (23.6) (+14.2%).
- Liquid biopsy-related tickers: TROV, OTCQX:RHHBY, BIOC, OCX, ILMN, TECH, FMI, GHDX, PRPO, OTCPK:MXDHF, ZOMHF, NSTG
Guardant Health on deck for IPO
Recommended For You
About GH Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
GH | - | - |
Guardant Health, Inc. |